Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Lab-on-chip molecular diagnostic test is launched for all major influenza types

Veredus Laboratories : 25 March, 2008  (New Product)
Veredus Laboratories and STMicroelectronics has launched VereFlu, a portable lab-on-chip application for rapid detection of all major influenza types at the point of need.
The lab-on-chip solution was successfully evaluated at the National University Hospital of Singapore.

Unlike existing diagnostic methods, VereFlu is a breakthrough molecular diagnostic test that can detect infection with high accuracy and sensitivity, within two hours providing genetic information of the infection that traditionally would take days to weeks to learn. With its high level of automation, users outside the traditional lab environment can easily perform the tests at the point of need.

Combining STMicroelectronics' In-Check lab-on-chip platform with Veredus' bio-application capability, VereFlu is the market's first test that has integrated two powerful molecular biological applications in a lab-on-chip the size of a fingernail. The platform can identify and differentiate human strains of Influenza A and B viruses, including the Avian Flu strain H5N1, in a single test.

'We are pleased to report that our evaluation trials show the suitability of the VereFlu diagnostic application for field testing and deployment,' said associate professor Raymond Lin, head of microbiology, Department of Laboratory Medicine, National University Hospital in Singapore. 'The diagnostic reliability of this novel device makes it a powerful weapon against future influenza pandemics.'

'VereFlu will enable healthcare professionals to effectively monitor mutations of flu viruses and quickly identify the main strain of the season,' said Dr Rosemary Tan, chief executive officer of Veredus Laboratories. 'This unique capability can significantly increase the effectiveness of flu vaccination and reduce public health risks associated with the emergence of a new flu virus.'

'The launch of VereFlu marks a substantial breakthrough in enabling rapid identification of the infectious agent to limit the spread of the disease and speed patients' treatment,' said Gian Luca Bertino, corporate vice president and general manager of ST's Computer Peripherals Group. 'The combination of Veredus' diagnostic know-how with ST's microfluidic lab-on-chip technology has bred the market's first solution that detects multiple flu viruses at the point of need in a fraction of the time, cost, and complexity of conventional diagnostic systems.'

A miniature laboratory on a chip, ST's In-Check platform allows users to accurately and reliably process and analyse minute patient samples - human blood, serum or respiratory swabs - on a single disposable thumbnail-sized chip. This approach reduces the time and complexity, as well as the risk of cross-contamination inherent in conventional analysis methods.

Encouraged by the success of the VereFlu project, STMicroelectronics and Veredus Laboratories have set up a joint lab, where experts from both companies will work together on the development of new biomedical applications based on ST's In-Check lab-on-chip platform. Future application areas of interest include other infectious diseases, oncology and heart-disease markers. The new ST/Veredus biomedical laboratory, called the Bio-Application Lab, is located at the Science Park in Singapore and will be managed by Dr Rosemary Tan, chief executive officer of Veredus.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo